PT  - JOURNAL ARTICLE
AU  - Furong Liu
AU  - Xin Long
AU  - Wenbin Zou
AU  - Minghao Fang
AU  - Wenjuan Wu
AU  - Wei Li
AU  - Bixiang Zhang
AU  - Wanguang Zhang
AU  - Xiaoping Chen
AU  - Zhanguo Zhang
TI  - Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 Infection
AID  - 10.1101/2020.02.28.20029181
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.28.20029181
4099  - http://medrxiv.org/content/early/2020/03/03/2020.02.28.20029181.short
4100  - http://medrxiv.org/content/early/2020/03/03/2020.02.28.20029181.full
AB  - The ongoing outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in the end of 2019 in China has triggered a global public health crisis. Previous studies have shown that SARS-CoV-2 infects cells by binding angiotensin-converting enzyme 2 (ACE2), which is the same as SARS-CoV. The expression and distribution of ACE2 in the pancreas are unknown. At the same time, the injury of pancreas after SARS-CoV-2 infection has not been concerned. Here, we collected public datasets (bulk RNA-seq and single-cell RNA-seq) to indicate the expression and the distribution of ACE2 in pancreas (in both exocrine glands and islets). And further, clinical data including mild and severe patients with COVID-19 demonstrated there existed mild pancreatitis. In the 67 severe cases, 11 patients (16.41%) showed elevated levels of both amylase and lipase, and 5 patients (7.46%) showed imaging alterations. Only one patient (1.85%) showed elevated levels of both amylase and lipase in 54 mild cases, without imaging changes. Our study revealed the phenomenon and possible cause of mild pancreatic injury in patients with COVID-19. This suggests that pancreatitis after SARS-CoV-2 infection should also be paid attention in clinical work.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the State Key Project on Infection Disease of China (No. 2018ZX10723204-003); the Chinese Ministry of Public Health for Key Clinical Project (No. [2010] 493-51); National Natural Science Foundation of China (81502530, 81874189 and 81874149).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in the manuscript.